Strategic moves crimp Takeda's year-end figures
This article was originally published in Scrip
Executive Summary
The acquisition of Millennium Pharmaceuticals, the dissolution of the TAP US joint venture with Abbott and currency effects all took their toll on Takeda's top and bottom lines for the fiscal year to March 31st.